Flossbach Von Storch SE Invests $464.51 Million in Stryker Corporation $SYK

Flossbach Von Storch SE bought a new stake in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,475,371 shares of the medical technology company’s stock, valued at approximately $464,506,000. Stryker comprises approximately 2.1% of Flossbach Von Storch SE’s investment portfolio, making the stock its 17th biggest holding. Flossbach Von Storch SE owned 0.38% of Stryker at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. VanderPol Investments L.L.C. boosted its stake in Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after buying an additional 28 shares during the period. KCM Investment Advisors LLC raised its stake in shares of Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after acquiring an additional 28 shares during the period. Rossby Financial LCC lifted its holdings in shares of Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares during the last quarter. Tcfg Wealth Management LLC lifted its holdings in shares of Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after acquiring an additional 29 shares during the last quarter. Finally, West Michigan Advisors LLC boosted its stake in shares of Stryker by 0.4% during the 4th quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company’s stock worth $2,631,000 after purchasing an additional 30 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on SYK. Barclays cut their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research note on Friday, May 1st. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Piper Sandler decreased their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Up 2.7%

Shares of NYSE:SYK opened at $340.20 on Thursday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The stock has a market cap of $130.49 billion, a P/E ratio of 35.25, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The business’s 50 day moving average is $326.19 and its 200 day moving average is $332.95. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 315,370 shares of company stock worth $98,463,501 over the last three months. 4.60% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.